Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03577548
Other study ID # P/2016/290
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 2, 2016
Est. completion date August 2018

Study information

Verified date July 2018
Source Centre Hospitalier Universitaire de Besancon
Contact Rose-Angélique BELOT
Email rose-angelique.belot@univ-fcomte.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to describe the psychological and social characteristics of patients suffering from primary headache and monitored in Neurology department of Besançon University Hospital


Description:

The aim of our study is to describe the psychological patterns in a population of patients suffering of episodic migraine or chronic migraine with and without medication overuse and the level of disability.

Data about migraine characteristics will be obtained using a standardized questionnaire.

Socio-demographic data will be obtained for all patients including gender, age, educational level and professional status.

A booklet of 10 self-administered questionnaires will permit to measure psychological factors such as depression, anxiety, alexithymia...


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date August 2018
Est. primary completion date August 2018
Accepts healthy volunteers No
Gender All
Age group 25 Years to 60 Years
Eligibility Inclusion Criteria:

- Patients from 25 to 60 ans y.o suffering from primary headache and monitored in the Neurology department of Besançon University Hospital

Exclusion Criteria:

- Patients with former or current psychic troubles

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Auto- questionnaires
10 auto-questionnaires are submitted to the patient during his/her consultation (which is part of the standard care).

Locations

Country Name City State
France CHU de Besançon Besançon

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Besancon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Descriptive analysis of socio-demographic questionnaire Composite outcome assessed with 10 questionnaires are submitted to the patients and all their results are combined in order to identify psychological and social characteristics of the patients:
Quantitative variables will be mean, standard deviation, median and minimal/maximal values. Qualitative variables will be described by frequency and proportion of each class.
Day 1
Primary Descriptive analysis of Short Form 36 (SF 36) Health Survey Composite outcome assessed with 10 questionnaires are submitted to the patients and all their results are combined in order to identify psychological and social characteristics of the patients:
Quantitative variables will be mean, standard deviation, median and minimal/maximal values. Qualitative variables will be described by frequency and proportion of each class.
This questionnaire asseses quality of life.
Day 1
Primary Descriptive analysis of General Health Questionnaire 12 Composite outcome assessed with 10 questionnaires are submitted to the patients and all their results are combined in order to identify psychological and social characteristics of the patients:
Quantitative variables will be mean, standard deviation, median and minimal/maximal values. Qualitative variables will be described by frequency and proportion of each class.
Ranges for this questionnaire: 0 - 1 : no psychological distress / 2 - 3 : psychological problems / 4 - 48 : suspicion of mental illness.
Day 1
Primary Descriptive analysis of Cungi test Composite outcome assessed with 10 questionnaires are submitted to the patients and all their results are combined in order to identify psychological and social characteristics of the patients:
Quantitative variables will be mean, standard deviation, median and minimal/maximal values. Qualitative variables will be described by frequency and proportion of each class.
Ranges for this questionnaire: 12 - 19 : very low level of stress / 20 - 30 : low level of stress / 31 - 45 : high level of stress / > 45 : very high level of stress.
Day 1
Primary Descriptive analysis of State-Trait Anxiety Inventory Y-A Composite outcome assessed with 10 questionnaires are submitted to the patients and all their results are combined in order to identify psychological and social characteristics of the patients:
Quantitative variables will be mean, standard deviation, median and minimal/maximal values. Qualitative variables will be described by frequency and proportion of each class.
Ranges for this questionnaire (current anxiety): < 36 : very low / 36 à 45 : low / 46 à 55 : medium / 56 à 65 : high / > 65 : very high.
Day 1
Primary Descriptive analysis of State-Trait Anxiety Inventory Y-B Composite outcome assessed with 10 questionnaires are submitted to the patients and all their results are combined in order to identify psychological and social characteristics of the patients:
Quantitative variables will be mean, standard deviation, median and minimal/maximal values. Qualitative variables will be described by frequency and proportion of each class.
Ranges for this questionnaire (general anxiety): < 36 : very low / 36 à 45 : low / 46 à 55 : medium / 56 à 65 : high / > 65 : very high.
Day 1
Primary Descriptive analysis of Beck Depression Inventory Composite outcome assessed with 10 questionnaires are submitted to the patients and all their results are combined in order to identify psychological and social characteristics of the patients:
Quantitative variables will be mean, standard deviation, median and minimal/maximal values. Qualitative variables will be described by frequency and proportion of each class.
Ranges for this questionnaire: 0 - 4 : no depression / 5 - 7 : mild depression / 8 - 15 : moderate depression / > 15 : severe depression.
Day 1
Primary Descriptive analysis of Social Support Questionnaire 6 Composite outcome assessed with 10 questionnaires are submitted to the patients and all their results are combined in order to identify psychological and social characteristics of the patients:
Quantitative variables will be mean, standard deviation, median and minimal/maximal values. Qualitative variables will be described by frequency and proportion of each class.
This questionnaire assesses satisfaction upon social support.
Day 1
Primary Descriptive analysis of Toronto Alexithymia Scale 20 Composite outcome assessed with 10 questionnaires are submitted to the patients and all their results are combined in order to identify psychological and social characteristics of the patients:
Quantitative variables will be mean, standard deviation, median and minimal/maximal values. Qualitative variables will be described by frequency and proportion of each class.
Three levels for alexythimia: < 44 : non-alexithymia / 44 à 55 : possible alexithymia / > 55 : alexithymia.
Day 1
Primary Descriptive analysis of Bartholomew Relationship Scales Questionnaire Composite outcome assessed with 10 questionnaires are submitted to the patients and all their results are combined in order to identify psychological and social characteristics of the patients:
Quantitative variables will be mean, standard deviation, median and minimal/maximal values. Qualitative variables will be described by frequency and proportion of each class.
Four levels for this questionnaire: Secure, Preoccupied, Dismissing and Fearful.
Day 1
See also
  Status Clinical Trial Phase
Recruiting NCT05503082 - Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies Phase 4
Completed NCT04905654 - Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura N/A
Completed NCT04111484 - Adrenomedullin Effect on Migraine Without Patients N/A
Recruiting NCT04091789 - Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea Phase 2
Completed NCT03337620 - Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine Phase 3
Completed NCT02259387 - Adolescents With Migraine: What's Stress Got To Do With It?
Completed NCT05658185 - Migraine Difficult to Treat: the Importance of Psychological Care in the Chronic Patient N/A
Completed NCT05001399 - Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain N/A
Completed NCT03490500 - Using the S100B Protein for Emergency Headache Management Care (S100)
Completed NCT03075020 - Carbon Monoxide Migraine-inducing Effects in Patients With Migraine Without Aura. N/A
Recruiting NCT03472092 - Mind and Body Approaches to Pain Reduction in Youth With Migraine Phase 2
Enrolling by invitation NCT04976985 - Osteopathic Manipulative Treatment and Migraine Headaches N/A
Active, not recruiting NCT04372264 - Intravenous Paracetamol, Dexketoprofen and Ibuprofen in the Treatment of Acute Migraine Attack Headache Phase 4
Recruiting NCT04623203 - The Prognosis of Migraine and Tension-Type Headache in Children and Adolescents
Completed NCT04577443 - The Effect of Adenosine on Cranial Hemodynamic, Headache and Migraine Induction Properties. N/A
Completed NCT03560024 - The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by Magnetic Resonance Angiography (MRA) on Healthy Volunteers N/A
Completed NCT03228355 - Headache Inducing Effect of Cromakalim in Migraine Patients N/A
Completed NCT02438553 - Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain N/A
Recruiting NCT04715685 - Mind Body Balance for Pediatric Migraine N/A
Completed NCT05853900 - Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Phase 3